Clinical Trials
40 trialsSIB
Medical College of Wisconsin
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
PARTIQoL
Massachusetts General Hospital
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
REVELUTION
Emory University
SOAR
University of Utah
Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)
Memorial Sloan Kettering Cancer Center
PEACE 7
UNICANCER
PROST-ART
IRCCS San Raffaele
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
PARTOM
First Hospital of China Medical University
TTOPROST/OBS
Fundacion IMIM
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
UNICANCER
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
Wake Forest University Health Sciences
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
OHSU Knight Cancer Institute
DOP
The Netherlands Cancer Institute
HypoF-SBRT
University Hospital Freiburg
Tumor TARGET Prostate Cancer
University Health Network, Toronto
PROSTRACK
Centre Georges Francois Leclerc
COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer
Samsung Medical Center
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
FACBC Outcomes for Post Prostatectomy
Emory University
THRIP
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metabolomic Study for Localized Prostate Cancer
Georgetown University
Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer
Georgetown University
CCRO025
University of California, Davis
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
University of California, San Francisco
RCMI PELVIS
Institut Cancerologie de l'Ouest
Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
University of Texas Southwestern Medical Center
Hypofractionated Radiation Therapy in Prostate Cancer
University Hospital, Geneva
Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer
Mayo Clinic
MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate
Abramson Cancer Center at Penn Medicine
Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine
University of Kentucky
Hypofractionated Whole Pelvic Radiotherapy of the Prostate
University of California, San Francisco
Intensity-modulated Radiation Therapy From 70Gy to 80Gy in Localized Prostate Cancer
Institut de Cancérologie de Lorraine
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
University of Kansas Medical Center
The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer
AHS Cancer Control Alberta
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Benaroya Research Institute
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
Nova Scotia Cancer Centre
Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer
Mayo Clinic